Creative Biolabs Launches Advanced Neuroscience Platforms to Address Growing Neurodegenerative Disease Research Needs
Creative Biolabs has introduced specialized neuroscience research platforms targeting Alzheimer's and other neurodegenerative diseases, providing critical tools for studying cellular mechanisms in both peripheral and central nervous systems to accelerate drug development and mechanistic studies.
Creative Biolabs has unveiled a suite of advanced neuroscience platforms designed to accelerate brain research amid rising global rates of neurodegenerative diseases. The World Health Organization reports more than 55 million people currently live with dementia worldwide, with Alzheimer's disease accounting for up to 70% of dementia cases, driving demand for translational neuroscience tools.
The company's new Schwann Cell Assay platform focuses on the peripheral nervous system, isolating Schwann cells from human, mouse, and rat species. This platform supports co-culture systems with neurons, enabling scientists to assess critical functional measures including neurotrophic factor secretion and myelination potential, both fundamental to regenerative medicine research.
For central nervous system research, Creative Biolabs launched its microglia phagocytosis assay service, utilizing live-cell imaging and fluorescently labelled bioparticles to visualize microglial phagocytic function in real time. Microglia, as the brain's resident immune cells, play crucial roles in managing neural homeostasis, responding to neuroinflammation, and eliminating pathological protein aggregates.
The company has also developed comprehensive preclinical assessment services for Alzheimer's disease models, capable of creating both 2D and 3D platforms that represent key disease aspects including amyloid deposition, tauopathy, and neuroinflammation. These models can simulate both familial and sporadic Alzheimer's disease forms using patient-derived induced pluripotent stem cells, providing more rigorous contexts for drug screening and mechanistic studies.
A company spokesperson stated their aim is to provide researchers with the right resources to advance neuroscience, particularly given the urgent need for effective treatments against neurodegenerative conditions. The platforms address critical gaps in current research methodologies by offering species-specific cellular models and real-time functional assessment capabilities that could significantly accelerate therapeutic development timelines.